Floatz logo

Abemaciclib

Hormone Receptor-Positive Breast Cancer

BeOne MedicinesSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

111 Active assets in the Hormone Receptor-Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Everolimus
Ellipses Pharma
Phase 4BBB
ANASTROZOLE
University of Illinois at Chicago
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB
Ribociclib
BeOne Medicines
Phase 4BBB

View all 50 →

Same molecule, other indications

Abemaciclib is also rated in:

estrogen-receptor positive breast cancerActive
BB
Indicative · Phase 3
70 / 100
View asset →
metastatic neoplasmActive
BB
Indicative · Phase 4
67 / 100
View asset →
ovarian carcinomaActive
BB
Indicative · Phase 2
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →